{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:50:36Z","timestamp":1793479836127,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011789","name":"Jilin Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["20190304042YY"],"award-info":[{"award-number":["20190304042YY"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011789","name":"Jilin Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["20200201488JC"],"award-info":[{"award-number":["20200201488JC"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970628"],"award-info":[{"award-number":["81970628"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejphar.2021.174503","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:23:14Z","timestamp":1632097394000},"page":"174503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Pirfenidone is a renal protective drug: Mechanisms, signalling pathways, and preclinical evidence"],"prefix":"10.1016","volume":"911","author":[{"given":"Xue","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2029-4432","authenticated-orcid":false,"given":"Ping","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7952-6579","authenticated-orcid":false,"given":"Yan","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0029-0872","authenticated-orcid":false,"given":"Ping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.174503_bib1","doi-asserted-by":"crossref","first-page":"104694","DOI":"10.1016\/j.phrs.2020.104694","article-title":"Pirfenidone is a cardioprotective drug: mechanisms of action and preclinical evidence","volume":"155","author":"Aimo","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.ejphar.2021.174503_bib2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0006-2952(02)01213-3","article-title":"Effect of pirfenidone against vanadate-induced kidney fibrosis in rats","volume":"64","author":"Al-Bayati","year":"2002","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2021.174503_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jss.2004.12.007","article-title":"The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity","volume":"125","author":"Brook","year":"2005","journal-title":"J. Surg. Res."},{"issue":"12","key":"10.1016\/j.ejphar.2021.174503_bib4","article-title":"Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5\/6 nephrectomized rats","volume":"8","author":"Chen","year":"2013","journal-title":"PLOS ONE"},{"issue":"6","key":"10.1016\/j.ejphar.2021.174503_bib5","doi-asserted-by":"crossref","first-page":"F676","DOI":"10.1152\/ajprenal.00507.2012","article-title":"Pirfenidone inhibits macrophage infiltration in 5\/6 nephrectomized rats","volume":"304","author":"Chen","year":"2013","journal-title":"Am. J. Physiol. Renal. Physiol."},{"issue":"11","key":"10.1016\/j.ejphar.2021.174503_bib6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/ki.2009.86","article-title":"Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy","volume":"75","author":"Chevalier","year":"2009","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.ejphar.2021.174503_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/13543780903501539","article-title":"Pirfenidone: an anti-fibrotic therapy for progressive kidney disease","volume":"19","author":"Cho","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"5","key":"10.1016\/j.ejphar.2021.174503_bib8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.01050207","article-title":"Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis","volume":"2","author":"Cho","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.ejphar.2021.174503_bib9","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3390\/cells9030775","article-title":"Pirfenidone inhibits cell proliferation and collagen I production of primary human intestinal fibroblasts","volume":"9","author":"Cui","year":"2020","journal-title":"Cells."},{"issue":"9","key":"10.1016\/j.ejphar.2021.174503_bib10","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1681\/ASN.2009010019","article-title":"Wnt\/beta-catenin signaling promotes podocyte dysfunction and albuminuria","volume":"20","author":"Dai","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.ejphar.2021.174503_bib11","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.dld.2004.05.012","article-title":"The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2","volume":"36","author":"Di Sario","year":"2004","journal-title":"Dig. Liver Dis."},{"issue":"5","key":"10.1016\/j.ejphar.2021.174503_bib12","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1096\/fj.201600892RR","article-title":"Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors","volume":"31","author":"Didiasova","year":"2017","journal-title":"Faseb J."},{"issue":"5","key":"10.1016\/j.ejphar.2021.174503_bib13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1681\/ASN.2011060614","article-title":"Sonic hedgehog signaling mediates epithelial-mesenchymal communication and promotes renal fibrosis","volume":"23","author":"Ding","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.ejphar.2021.174503_bib14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrneph.2016.54","article-title":"Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog","volume":"12","author":"Edeling","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"issue":"4","key":"10.1016\/j.ejphar.2021.174503_bib15","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.ajpath.2011.12.039","article-title":"Hedgehog-Gli pathway activation during kidney fibrosis","volume":"180","author":"Fabian","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.ejphar.2021.174503_bib16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/17512433.2017.1295846","article-title":"Pirfenidone for the treatment of idiopathic pulmonary fibrosis","volume":"10","author":"George","year":"2017","journal-title":"Expet Rev. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.ejphar.2021.174503_bib17","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1007\/s12325-019-01052-y","article-title":"Cardiovascular risks, bleeding risks, and clinical events from 3 phase III trials of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"36","author":"Glassberg","year":"2019","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.ejphar.2021.174503_bib18","first-page":"453","article-title":"Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis","volume":"14","author":"Hewitson","year":"2001","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ejphar.2021.174503_bib19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-physiol-022516-034227","article-title":"Mechanisms of renal fibrosis","volume":"80","author":"Humphreys","year":"2018","journal-title":"Annu. Rev. Physiol."},{"issue":"5","key":"10.1016\/j.ejphar.2021.174503_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1023\/A:1007068313370","article-title":"Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation","volume":"24","author":"Iyer","year":"2000","journal-title":"Inflammation"},{"issue":"6","key":"10.1016\/j.ejphar.2021.174503_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2220\/biomedres.34.309","article-title":"Renoprotective mechanisms of pirfenidone in hypertension-induced renal injury: through anti-fibrotic and anti-oxidative stress pathways","volume":"34","author":"Ji","year":"2013","journal-title":"Biomed. Res."},{"issue":"9","key":"10.1016\/j.ejphar.2021.174503_bib22","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J. Rheumatol."},{"issue":"22","key":"10.1016\/j.ejphar.2021.174503_bib23","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"146","key":"10.1016\/j.ejphar.2021.174503_bib24","doi-asserted-by":"crossref","first-page":"170057","DOI":"10.1183\/16000617.0057-2017","article-title":"Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis","volume":"26","author":"Lancaster","year":"2017","journal-title":"Eur. Respir. Rev."},{"issue":"8","key":"10.1016\/j.ejphar.2021.174503_bib25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/nep.12831","article-title":"Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis","volume":"22","author":"Li","year":"2017","journal-title":"Nephrology"},{"issue":"1","key":"10.1016\/j.ejphar.2021.174503_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12882-019-1364-4","article-title":"Pirfenidone prevents acute kidney injury in the rat","volume":"20","author":"Lima-Posada","year":"2019","journal-title":"BMC Nephrol."},{"issue":"6","key":"10.1016\/j.ejphar.2021.174503_bib27","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.3892\/mmr.2017.6461","article-title":"Role of the Wnt\/\u03b2-catenin signaling pathway in inducing apoptosis and renal fibrosis in 5\/6-nephrectomized rats","volume":"15","author":"Lin","year":"2017","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.ejphar.2021.174503_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12890-017-0405-7","article-title":"Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2\/Bach1 equilibrium","volume":"17","author":"Liu","year":"2017","journal-title":"BMC Pulm. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2021.174503_bib29","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/ndt\/gft267","article-title":"Transforming growth factor-\u03b2 and the progression of renal disease","volume":"29","author":"Loeffler","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"10.1016\/j.ejphar.2021.174503_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s10020-020-00173-3","article-title":"Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt\/GSK-3\u03b2\/\u03b2-catenin and TGF-\u03b21\/Smad2\/3 signaling pathways","volume":"26","author":"Lv","year":"2020","journal-title":"Mol. Med."},{"issue":"5","key":"10.1016\/j.ejphar.2021.174503_bib31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.bjp.0704131","article-title":"Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats","volume":"133","author":"Miric","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.ejphar.2021.174503_bib32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/A:1007023532508","article-title":"Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals","volume":"204","author":"Misra","year":"2000","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2021.174503_bib33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.addr.2017.12.019","article-title":"Targeting renal fibrosis: mechanisms and drug delivery systems","volume":"129","author":"Nastase","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.ejphar.2021.174503_bib34","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.3390\/ijms21082951","article-title":"Roles of Nrf2 in protecting the kidney from oxidative damage","volume":"21","author":"Nezu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9779","key":"10.1016\/j.ejphar.2021.174503_bib35","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejphar.2021.174503_bib36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3346\/jkms.2003.18.4.527","article-title":"Pirfenidone suppressed the development of glomerulosclerosis in the FGS\/Kist mouse","volume":"18","author":"Park","year":"2003","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.ejphar.2021.174503_bib37","doi-asserted-by":"crossref","first-page":"116666","DOI":"10.1016\/j.lfs.2019.116666","article-title":"Renoprotective effects of pirfenidone on chronic renal allograft dysfunction by reducing renal interstitial fibrosis in a rat model","volume":"233","author":"Qiu","year":"2019","journal-title":"Life Sci."},{"issue":"8","key":"10.1016\/j.ejphar.2021.174503_bib38","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1681\/ASN.2008090931","article-title":"Pirfenidone is renoprotective in diabetic kidney disease","volume":"20","author":"RamachandraRao","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.ejphar.2021.174503_bib39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pupt.2009.03.003","article-title":"Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults","volume":"22","author":"Rubino","year":"2009","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.ejphar.2021.174503_bib40","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: molecular mechanisms and potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejphar.2021.174503_bib41","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3389\/fgene.2019.01103","article-title":"Hedgehog signal and genetic disorders","volume":"10","author":"Sasai","year":"2019","journal-title":"Front. Genet."},{"issue":"3","key":"10.1016\/j.ejphar.2021.174503_bib42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12272-019-01177-2","article-title":"Filtering through the role of NRF2 in kidney disease","volume":"43","author":"Schmidlin","year":"2020","journal-title":"Arch. Pharm. Res."},{"issue":"3","key":"10.1016\/j.ejphar.2021.174503_bib43","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41581-020-00343-w","article-title":"WNT-\u03b2-catenin signalling - a versatile player in kidney injury and repair","volume":"17","author":"Schunk","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejphar.2021.174503_bib44","doi-asserted-by":"crossref","first-page":"118454","DOI":"10.1016\/j.lfs.2020.118454","article-title":"Pirfenidone attenuates gentamicin-induced acute kidney injury by inhibiting inflammasome-dependent NLRP3 pathway in rats","volume":"260","author":"Sharawy","year":"2020","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.ejphar.2021.174503_bib45","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1681\/ASN.2010101049","article-title":"Pirfenidone for diabetic nephropathy","volume":"22","author":"Sharma","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2021.174503_bib46","doi-asserted-by":"crossref","first-page":"569322","DOI":"10.3389\/fphys.2020.569322","article-title":"New insights into the role and mechanism of partial epithelial-mesenchymal transition in kidney fibrosis","volume":"11","author":"Sheng","year":"2020","journal-title":"Front. Physiol."},{"issue":"3","key":"10.1016\/j.ejphar.2021.174503_bib47","first-page":"1593","article-title":"Pirfenidone inhibits epidural scar fibroblast proliferation and differentiation by regulating TGF-\u03b21-induced Smad-dependent and -independent pathways","volume":"11","author":"Shi","year":"2019","journal-title":"Am. J. Transl. Res."},{"issue":"10","key":"10.1016\/j.ejphar.2021.174503_bib48","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0091270007304104","article-title":"Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers","volume":"47","author":"Shi","year":"2007","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2021.174503_bib49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1034\/j.1600-6143.2002.020201.x","article-title":"Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity","volume":"2","author":"Shihab","year":"2002","journal-title":"Am. J. Transplant."},{"issue":"4","key":"10.1016\/j.ejphar.2021.174503_bib50","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.TP.0000151721.99418.48","article-title":"Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity","volume":"79","author":"Shihab","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.ejphar.2021.174503_bib51","first-page":"S239","article-title":"Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy","volume":"63","author":"Shimizu","year":"1997","journal-title":"Kidney Int. Suppl."},{"issue":"1","key":"10.1016\/j.ejphar.2021.174503_bib52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1523-1755.1998.00962.x","article-title":"Pirfenidone improves renal function and fibrosis in the post-obstructed kidney","volume":"54","author":"Shimizu","year":"1998","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.ejphar.2021.174503_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172592","article-title":"Suppression of TGF-\u03b2 pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro","volume":"12","author":"Stahnke","year":"2017","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.ejphar.2021.174503_bib54","first-page":"3907","article-title":"Pirfenidone suppresses TGF-\u03b21-induced human intestinal fibroblasts activities by regulating proliferation and apoptosis via the inhibition of the Smad and PI3K\/AKT signaling pathway","volume":"18","author":"Sun","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2021.174503_bib55","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2014.05.015","article-title":"Antiproteinuric effect of pirfenidone in a rat model of anti-glomerular basement membrane glomerulonephritis","volume":"737","author":"Takakura","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.ejphar.2021.174503_bib56","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejphar.2009.12.011","article-title":"Renoprotective properties of pirfenidone in subtotally nephrectomized rats","volume":"629","author":"Takakuta","year":"2010","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2021.174503_bib57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s002280050252","article-title":"Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients","volume":"52","author":"Taniyama","year":"1997","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.ejphar.2021.174503_bib58","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1248\/bpb.b13-00452","article-title":"Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis","volume":"36","author":"Togami","year":"2013","journal-title":"Biol. Pharm. Bull."},{"issue":"4","key":"10.1016\/j.ejphar.2021.174503_bib59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/bdd.1932","article-title":"Pharmacokinetic evaluation of tissue distribution of pirfenidone and its metabolites for idiopathic pulmonary fibrosis therapy","volume":"36","author":"Togami","year":"2015","journal-title":"Biopharm Drug Dispos."},{"issue":"5","key":"10.1016\/j.ejphar.2021.174503_bib60","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/resp.12297","article-title":"Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"19","author":"Valeyre","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.ejphar.2021.174503_bib61","doi-asserted-by":"crossref","first-page":"108451","DOI":"10.1016\/j.jnutbio.2020.108451","article-title":"Nrf2 participates in the anti-apoptotic role of zinc in Type 2 diabetic nephropathy through Wnt\/\u03b2-catenin signaling pathway","volume":"84","author":"Wang","year":"2020","journal-title":"J. Nutr. Biochem."},{"issue":"2","key":"10.1016\/j.ejphar.2021.174503_bib62","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/1756-185X.13247","article-title":"Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease","volume":"21","author":"Xiao","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.ejphar.2021.174503_bib63","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1177\/0300060519876796","article-title":"GSTA3 regulates TGF-\u03b21-induced renal interstitial fibrosis in NRK-52E cells as a component of the PI3K-Keap1\/Nrf2 pathway","volume":"47","author":"Xiao","year":"2019","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.ejphar.2021.174503_bib64","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3389\/fcell.2019.00379","article-title":"Effect and regulation of the NLRP3 inflammasome during renal fibrosis","volume":"7","author":"Zhang","year":"2020","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.ejphar.2021.174503_bib65","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbrc.2021.01.055","article-title":"Pirfenidone inhibits fibroblast proliferation, migration or adhesion and reduces epidural fibrosis in rats via the PI3K\/AKT signaling pathway","volume":"547","author":"Zhang","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.ejphar.2021.174503_bib66","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1681\/ASN.2013080893","article-title":"Sonic hedgehog is a novel tubule-derived growth factor for interstitial fibroblasts after kidney injury","volume":"25","author":"Zhou","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.ejphar.2021.174503_bib67","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s11427-016-0020-y","article-title":"Sonic hedgehog signaling in kidney fibrosis: a master communicator","volume":"59","author":"Zhou","year":"2016","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.ejphar.2021.174503_bib68","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.12659\/MSM.907891","article-title":"Pirfenidone inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells by inhibiting the wnt\/\u03b2-catenin signaling pathway","volume":"23","author":"Zou","year":"2017","journal-title":"Med. Sci. Monit."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921006579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921006579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:14:32Z","timestamp":1762143272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921006579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":68,"alternative-id":["S0014299921006579"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174503","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pirfenidone is a renal protective drug: Mechanisms, signalling pathways, and preclinical evidence","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"174503"}}